A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Phase 3 Recruiting 180 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

Timeline

Start: 2025-02-07
Primary completion: 2028-02-25
Completion: 2033-02-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remibrutinib	Small molecule	—	Oral

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Summary

Timeline

Drugs

Indications